KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.18 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2021-11-15
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-09-30 was $272.00K.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-06-30 was $80.00K, a 12.09% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-03-31 was $829.00K, a 69.53% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $212.00K, a 66.88% decline from fiscal 2017.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $640.00K, a 15.57% decline from fiscal 2016.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $758.00K, a 275.25% increase from fiscal 2015.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $202.00K, a 87.35% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|---|---|
| 2021-09-30 | $272.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $352.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.18M 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $909.00K 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $829.00K 10-Q · filed 2021-05-12 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $91.00K derived: sum of 2 quarters · filed 2021-11-15 | $580.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $580.00K 10-Q · filed 2021-08-12 | $579.90K 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $489.00K 10-Q · filed 2021-05-12 | |||||
| 2019-09-30 | -$13.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $355.00K 10-Q · filed 2020-11-09 | $337.00K derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $13.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $368.20K 10-Q · filed 2020-08-06 | $350.20K derived: sum of 3 quarters · filed 2020-08-06 | $429.00K derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $355.00K 10-Q · filed 2020-05-06 | $337.00K derived: sum of 2 quarters · filed 2020-05-06 | $415.80K derived: sum of 3 quarters · filed 2020-05-06 | $415.80K derived: sum of 4 quarters · filed 2020-05-06 | ||
| 2018-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $60.80K derived: sum of 2 quarters · filed 2019-11-07 | $60.80K derived: sum of 3 quarters · filed 2019-11-07 | $212.00K 10-K · filed 2019-03-01 | ||
| 2018-09-30 | $78.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $78.80K derived: sum of 2 quarters · filed 2019-11-07 | $230.00K 10-Q · filed 2019-11-07 | $320.00K derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $151.20K 10-Q · filed 2019-08-08 | $151.00K 10-Q · filed 2018-08-03 | $241.20K derived: sum of 3 quarters · filed 2019-08-08 | $261.20K derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $151.20K 10-Q · filed 2019-05-08 | $151.17K 10-Q · filed 2018-05-11 | $241.20K derived: sum of 2 quarters · filed 2019-05-08 | $261.20K derived: sum of 3 quarters · filed 2019-05-08 | $768.34K derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $110.00K derived: sum of 2 quarters · filed 2019-03-01 | $617.14K derived: sum of 3 quarters · filed 2019-03-01 | $640.00K 10-K · filed 2019-03-01 | ||
| 2017-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $527.14K derived: sum of 2 quarters · filed 2018-11-13 | $550.00K 10-Q · filed 2018-11-13 | $588.00K derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2017-06-30 | $507.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $530.00K 10-Q · filed 2018-08-03 | $568.00K derived: sum of 3 quarters · filed 2018-08-03 | $814.00K derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | $22.86K 10-Q · filed 2018-05-11 | $60.86K derived: sum of 2 quarters · filed 2018-05-11 | $306.86K derived: sum of 3 quarters · filed 2018-05-11 | $405.12K derived: sum of 4 quarters · filed 2018-05-11 | ||
| 2016-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $284.00K derived: sum of 2 quarters · filed 2018-03-02 | $382.25K derived: sum of 3 quarters · filed 2018-03-02 | $758.00K 10-K · filed 2018-03-02 | ||
| 2016-09-30 | $246.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $344.25K derived: sum of 2 quarters · filed 2017-11-14 | $720.00K 10-Q · filed 2017-11-14 | -$675.00K derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-06-30 | $98.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $474.00K 10-Q · filed 2017-08-04 | -$921.00K derived: sum of 3 quarters · filed 2017-08-04 | -$719.00K derived: sum of 4 quarters · filed 2017-08-04 | ||
| 2016-03-31 | $375.75K 10-Q · filed 2017-05-05 | -$1.02M derived: sum of 2 quarters · filed 2017-05-05 | -$817.25K derived: sum of 3 quarters · filed 2017-05-05 | -$129.06K derived: sum of 4 quarters · filed 2017-05-05 | ||
| 2015-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$1.19M derived: sum of 2 quarters · filed 2017-02-23 | -$504.81K derived: sum of 3 quarters · filed 2017-02-23 | $202.00K 10-K · filed 2017-02-23 | ||
| 2015-09-30 | $202.00K 10-Q · filed 2015-11-12 | $890.19K derived: sum of 2 quarters · filed 2016-08-10 | $1.60M 10-Q · filed 2016-11-01 | |||
| 2015-06-30 | $688.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $1.13M 10-Q · filed 2016-08-10 | ||||
| 2015-03-31 | $443.81K 10-Q · filed 2016-05-13 | |||||
| 2014-12-31 | $1.60M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |